Besonprodil (CI-1041) is a drug which acts as an NMDA antagonist selective for the NR2B subunit. It is under development as a supplemental medication for Parkinson’s disease and has been shown in animals to be effective in counteracting the dyskinesias associated with long term treatment with levodopa and related drugs.
This page contains content from the copyrighted Wikipedia article "Besonprodil"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
